NCT01075191View on ClinicalTrials.gov

Kaletra: Therapy With Double Protease Inhibitors

CompletedOBSERVATIONAL
Enrollment

65

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions
Human Immunodeficiency Virus
Trial Locations (17)

10439

Site Reference ID/Investigator# 48283, Berlin

10551

Site Reference ID/Investigator# 28131, Berlin

10961

Site Reference ID/Investigator# 66422, Berlin

13347

Site Reference ID/Investigator# 28123, Berlin

42277

Site Reference ID/Investigator# 28126, Wuppertal

44137

Site Reference ID/Investigator# 28115, Dortmund

47800

Site Reference ID/Investigator# 5318, Krefeld

48143

Site Reference ID/Investigator# 28111, Münster

48149

Site Reference ID/Investigator# 28129, Münster

60311

Site Reference ID/Investigator# 28124, Frankfurt

60329

Site Reference ID/Investigator# 28127, Frankfurt

60596

Site Reference ID/Investigator# 28119, Frankfurt

67063

Site Reference ID/Investigator# 28112, Ludwigshafen

70197

Site Reference ID/Investigator# 28133, Stuttgart

80337

Site Reference ID/Investigator# 28118, Munich

80801

Site Reference ID/Investigator# 28113, Munich

D-10243

Site Reference ID/Investigator# 28109, Berlin

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01075191 - Kaletra: Therapy With Double Protease Inhibitors | Biotech Hunter | Biotech Hunter